In the ongoing phase 3 DREAMseq trial, patients with unresectable stage III or IV BRAFV600-mutant melanoma receive either BRAF/MEK inhibitor therapy with dabrafenib and trametinib and switch after progression to ICI therapy with ipilimumab and nivolumab, or the other way around [80]. Here, BRAF is linked to melanoma.